GSK Inks $360M Deal for Syndivia's Preclinical ADC Targeting mCRPC
Syndivia
Biological Engineering Company
GSK
Pharmaceutical R&D Manufacturer
▲November 6-7 The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators Summit Scan to register
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On October 27, GSK announced an agreement with Syndivia to obtain global exclusive development and commercialization rights for a preclinical ADC targeting metastatic castration-resistant prostate cancer (mCRPC).
According to the agreement, Syndivia will receive an upfront payment, as well asTotaling up to £268 million (approximately $360 million)The development and sales milestone payments, and will receive tiered royalties on global sales. GSK will assume responsibility for the development, manufacturing, and commercialization of this ADC project worldwide.
This novel ADC, utilizing Syndivia's next-generation GeminiMab conjugation technology, demonstrates enhanced anti-tumor activity and encouraging safety, showing potential to become a best-in-class drug. Preclinical studies indicate that even at higher doses, the ADC effectively shrinks tumors without a corresponding significant increase in side effects. The ADC can directly target tumors for precise treatment, filling the gap left by current therapies, while offering a more convenient treatment option for mCRPC patients in community healthcare settings.
GSK has been expanding its ADC drug portfolio in recent years through external acquisition:
On October 23, 2025, GSK announced that the FDA had approved Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent. Blenrep is a BCMA ADC developed by Seagen (which has been acquired by Pfizer). In December 2009, GSK reached an agreement with Seagen to obtain the rights for the research, development, manufacturing, and commercialization of the drug.
2In October 2023, GSK introduced the B7-H4 ADC drug HS-20089 from Hansoh Pharma in a deal worth $1.57 billion; in December 2023, GSK again introduced the B7-H3 ADC drug HS-20093 (GSK'227) from Hansoh Pharma in a deal worth $1.71 billion; in December 2024, GSK introduced a preclinical ADC drug DB-1324 from DualityBio in a deal worth $1.005 billion.
GSK is developing a series of innovative product lines, covering ADCs with different antigens and payloads, next-generation small molecules, and T-cell engagers.These diversified solutions (e.g., GSK'227 and this novel ADC)Enable GSK to advance potential treatment options for different stages and types of prostate cancer.
Copyright statement: This article is reproduced from the Biopharmaceutical Era, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceutical industry with the mission of "enabling the boundless flow of intelligence and networks." It has established an empowering system that covers the entire pharmaceutical industry chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it is building the infrastructure for the flow of value in China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources—this is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for leapfrog growth of enterprises.
